Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 30, 2024

SGLT2 Inhibitors in Hospitalised Patients With COVID-19

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
Lancet Diabetes Endocrinol 2024 Sep 05;[EPub Ahead of Print], C Vale, PJ Godolphin, D Fisher, PW Horby, MN Kosiborod, JS Hochman, K Webster, JPT Higgins, AD Althouse, O Berwanger, RHM Furtado, SB Gasparyan, R Haynes, GG Koch, M Landray, E Leifer, J Marshall, S Murthy, MD Neal, N Staplin, J Diaz, JAC Sterne, M Shankar-Hari

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading